These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20739765)

  • 21. Statins in the 21st century: end of the simple story?
    Doggrell SA
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1755-66. PubMed ID: 11772284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
    Cook JR; Yin D; Alemao E; Drummond M
    Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.
    Arca M; Gaspardone A
    Drugs; 2007; 67 Suppl 1():29-42. PubMed ID: 17910519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Primary prevention of coronary heart disease? What is cost effective in the clinical practice?].
    Kübler W
    Z Kardiol; 2005; 94 Suppl 3():III/92-9. PubMed ID: 16258799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.
    Lancet; 1996 Nov; 348(9038):1339-42. PubMed ID: 8918276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study].
    Szucs TD; Guggenberger G; Berger K; März W; Schäfer JR
    Herz; 1998 Aug; 23(5):319-29. PubMed ID: 9757381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statin therapy in the elderly: does it make good clinical and economic sense?
    Mungall MM; Gaw A; Shepherd J
    Drugs Aging; 2003; 20(4):263-75. PubMed ID: 12641482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statins and secondary prevention of coronary heart disease.
    Ahmed M; Griffiths P
    Br J Community Nurs; 2004 Apr; 9(4):160-5. PubMed ID: 15150487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials.
    Naci H; Brugts JJ; Fleurence R; Tsoi B; Toor H; Ades AE
    Eur J Prev Cardiol; 2013 Aug; 20(4):641-57. PubMed ID: 23447425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of statins.
    Huse DM; Russell MW; Miller JD; Kraemer DF; D'Agostino RB; Ellison RC; Hartz SC
    Am J Cardiol; 1998 Dec; 82(11):1357-63. PubMed ID: 9856919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.
    Tárraga-López PJ; Celada-Rodríguez A; Cerdán-Oliver M; Solera-Albero J; Ocaña-López JM; López-Cara MA; De Miguel-Clave J
    Pharmacoeconomics; 2005; 23(3):275-87. PubMed ID: 15836008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.
    Pletcher MJ; Lazar L; Bibbins-Domingo K; Moran A; Rodondi N; Coxson P; Lightwood J; Williams L; Goldman L
    Ann Intern Med; 2009 Feb; 150(4):243-54. PubMed ID: 19221376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statins for cardiovascular prevention according to different strategies: a cost analysis.
    Ito MK; Nanchen D; Rodondi N; Paccaud F; Waeber G; Vollenweider P; Marques-Vidal P
    Am J Cardiovasc Drugs; 2011; 11(1):33-44. PubMed ID: 21265581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
    Sever PS; Poulter NR; Dahlof B; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes G; Mehlsen J; Nieminen MS; O'Brien ET; Ostergren J;
    Eur Heart J; 2008 Feb; 29(4):499-508. PubMed ID: 18175773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Statins: intervention studies, facts and perspectives].
    Durlach V
    Ann Endocrinol (Paris); 2001 Feb; 62(1 Pt 2):133-44. PubMed ID: 11240416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?
    Maroo BP; Lavie CJ; Milani RV
    Drugs Aging; 2008; 25(8):649-64. PubMed ID: 18665658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
    Maclaine GD; Patel H
    Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.